US 12,358,906 B2
Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors
Christopher Adair, Woodstock (CA); Katsumasa Nakajima, Winchester, MA (US); Rukundo Ntaganda, Weymouth, MA (US); Julien Papillon, Somerville, MA (US); and Troy Douglas Smith, Nashua, NH (US)
Assigned to Novartis AG, Basel (CH)
Filed by NOVARTIS AG, Basel (CH)
Filed on Mar. 12, 2024, as Appl. No. 18/602,126.
Application 18/602,126 is a continuation of application No. 17/268,512, granted, now 11,958,846, previously published as PCT/IB2019/056847, filed on Aug. 12, 2019.
Claims priority of provisional application 62/765,138, filed on Aug. 17, 2018.
Prior Publication US 2024/0270738 A1, Aug. 15, 2024
Int. Cl. C07D 417/12 (2006.01); A61K 45/06 (2006.01)
CPC C07D 417/12 (2013.01) [A61K 45/06 (2013.01)] 13 Claims
 
1. A method of preparing a compound of formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein said method comprises the step of reacting compound of Formula (I-1):

OG Complex Work Unit Chemistry
with a compound of Formula (I-2):

OG Complex Work Unit Chemistry
in the presence of a base;
wherein
R is a H or a nitro group;
R1 and R6 are as defined below or groups which may undergo further transformation to provide a compound of Formula (I-1) wherein
R1 is selected from hydrogen, amino and hydroxy-substituted C1-2alkyl;
R2 is hydrogen;
R3 is selected from C1-2alkyl and halo-substituted-C1-2alkyl;
R4 is hydrogen;
R5 is selected from hydrogen and halo; and
R6 is selected from hydrogen and halo.